Pinealon — Clinical Reference

**⚠ Educational reference only — not medical advice.** This article is for research and educational reference. Always consult your own physician before considering any peptide protocol. See the full Disclaimer at the end of this article. ## Introduction Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as a short-peptide bioregulator derived from pineal-cortex polypeptide complexes. Investigational; no FDA-approved indication. ## Mechanism of Action The proposed mechanism centers on peptide-DNA interaction and transcriptional modulation, particularly in neural tissue. Pinealon is reported to upregulate protective gene expression, reduce oxidative stress, and modulate apoptosis signaling in stressed neurons. The molecular target receptor (if any) is incompletely defined. ## Research Indications Khavinson-school clinical literature reports use for age-related cognitive decline, acute hypoxic stress, and post-stroke recovery research. Western peer-reviewed data are limited. Best regarded as an investigational longevity / neuroprotection research peptide. ## Reconstitution Typical 10 mg lyophilized vial: add **5 mL of bacteriostatic water**, swirl gently. Final concentration **2000 mcg/mL (2 mg/mL)** — each 0.05 mL (5 units on a U-100 insulin syringe) delivers 100 mcg. ## Dosing Protocol (research literature) Russian research protocols typically use **100–300 mcg subcutaneously once daily** in short pulse courses — **10–20 consecutive days, repeated every 4–6 months** — rather than continuous dosing. Intranasal preparations are also documented at similar daily totals. ## Administration Subcutaneous injection into abdominal fat (rotate sites within each pulse course) or intranasal per Khavinson-school protocols. ## Storage & Handling Lyophilized: refrigerate (2–8°C). Reconstituted: refrigerate; stable approximately **14–21 days**. Protect from light. ## Side Effects Mild in available reports: injection-site reactions, occasional vivid dreaming. Long-term safety data are sparse and largely confined to a single research program. ## Contraindications Pregnancy, lactation, active CNS malignancy, and uncontrolled seizure disorders pending more characterization data. ## Monitoring Baseline cognitive instrument (MoCA or domain-specific tasks). Re-evaluate at the end of each pulse course and 4 weeks after. ## Disclaimer **This article is for informational and research-reference purposes only.** Nothing in this document constitutes medical advice, a prescription, or a recommendation from a physician. The reconstitution, dosing, and protocol information above reflects ranges commonly cited in published research and clinician-directed protocols — it is provided as reference material only, not as instructions, an endorsement of off-label use, or a substitute for individualized medical evaluation. **Customers should do their own research and consult their own physician** before considering any peptide protocol. Whether a given compound is appropriate for an individual — and at what dose, for what duration, and alongside what monitoring — is a decision that only a licensed clinician with knowledge of that individual's medical history, current medications, and conditions can make. The platform and the author make no claim that any compound described here is safe, effective, or appropriate for any particular person or purpose, and accept no responsibility for outcomes arising from self-directed use of the information.